Three Buyers Into This Antibody Biotech, Every Timeframe Green
AbCellera hunts for antibody-based drugs aimed at conditions nobody has good treatments for yet, and right now three insiders have stepped in over the past month. This one put $570,442 down at $10.64, an officer and a repeat buyer, which is the kind of stack that usually means something. The tape agrees for once. Trend reads Buy across short, medium, and long, momentum is green, and insiders on this name have averaged better than 18% over 90 days. With price sitting near $11.35 and the 8-day converging on the 20 from above, selling a put spread under the insider's $10.64 gets you paid to wait for an entry cheaper than the guy who knows this pipeline cold.
The Filing
| Ticker | ABCL |
| Company | AbCellera Biologics Inc. |
| Insider | Michael Hayden |
| Buy amount | $570,442 |
| Filing date | August 24, 2026 |
| Conviction | Interesting · 51/100 |
| Setup type | Trend Confirmation |
Ultimate members received this analysis in real time.